Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.49 |
| ▸ | BTK | Q06187 | 7/20 | 0.47 |
| ▸ | JAK3 | P52333 | 6/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806084 | 0.90 | UCHL3 (0.51) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18060894 | 0.87 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL18060670 | 0.86 | KCNQ3 (0.47) | — | |
| SCHEMBL18060776 | 0.85 | KDM4E (0.48) | — | |
| SCHEMBL18060636 | 0.80 | JAK3 (0.45) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18060638 | 0.80 | JAK3 (0.45) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18060747 | 0.79 | EGFR (0.45) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18060865 | 0.78 | KCNQ3 (0.42) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL12806196 | 0.78 | UCHL3 (0.54) | EGFRBTKJAK3JAK2JAK1 | |
| SCHEMBL18060648 | 0.77 | PLK4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205647-B1 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3205647-A2 | 2-(PYRIMIDIN-5-YL)-THIOPYRIMIDINE DERIVATIVES AS HSP70 AND HSC70 MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Memorial Sloan-Kettering Cancer Center (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2467142-B1 | 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders | SLOAN KETTERING INST CANCER (US) | 2016-09-21 | — | — | EP | disclosed |